SCHEMBL23217528

SCHEMBL23217528

CCOC(=O)Cc1ccccc1OCc1cc(Br)c2occc2c1OCc1ccncc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.41
KCNA2 P16389 1/20 0.39
KCNA5 P22460 1/20 0.39
KCNA1 Q09470 1/20 0.39
KCNA3 P22001 1/20 0.39
PRMT5 O14744 1/20 0.39
ABCB1 P08183 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CFD P00746 3/20 0.38
PIM1 P11309 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PTGER1 P34995 1/20 0.36
DUSP3 P51452 1/20 0.36
PTPN5 P54829 1/20 0.36
PTPN11 Q06124 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30009850 1.00 TBXAS1 (0.41) TBXAS1KCNA2KCNA5KCNA1KCNA3
SCHEMBL29672939 1.00 TBXAS1 (0.41) TBXAS1KCNA2KCNA5KCNA1KCNA3
SCHEMBL30010173 0.87 CFD (0.39) TBXAS1KCNA3MEN1KMT2ACFD
SCHEMBL23217835 0.87 CFD (0.39) TBXAS1KCNA3MEN1KMT2ACFD
SCHEMBL30010388 0.87 KCNA3 (0.41) TBXAS1KCNA3MEN1KMT2ADUSP3
SCHEMBL23217842 0.87 KCNA3 (0.41) TBXAS1KCNA3MEN1KMT2ADUSP3
SCHEMBL23217511 0.86 DUSP3 (0.42) TBXAS1MEN1KMT2ACFDDUSP3
SCHEMBL23217521 0.85 CFD (0.50) TBXAS1CFDPTGER1
SCHEMBL30009787 0.85 CFD (0.50) TBXAS1CFDPTGER1
SCHEMBL23217640 0.84 CFD (0.38) TBXAS1MEN1KMT2ACFDDUSP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TBXAS1 519/4885KCNA2 4398/4885KCNA5 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.